Argument
The DEA’s Aggregate Production Quota (APQ) system artificially restricts stimulant medication supply below the level of legitimate medical need, creating nationwide shortages for ADHD patients while failing to reduce actual drug abuse. The quota system is not a medical tool but a drug-war artifact: it treats ADHD patients as potential criminals and prioritizes liability management over patient outcomes. Australia (NSW) and New Zealand are already implementing the obvious fix — letting trained primary care physicians diagnose and prescribe — while the U.S. clings to a specialist-only gatekeeping model that creates access problems without improving safety.
Structure
Three sections following the newsletter’s Spark / Pattern / Protocol format:
- The Spark: When Drug Warriors Attack Medicine — DEA’s APQ system explained: annual production limits on stimulants, set below rising legitimate demand (adult ADHD diagnoses up, telehealth expansion post-pandemic). Quota system did not respond to demand increase. Result: patients calling dozens of pharmacies monthly, going weeks without medication.
- The Pattern: How Other Countries Figured Out the Obvious — NSW (Australia) reforms: GPs can now diagnose and treat ADHD, not just specialists. New Zealand: GPs and nurse practitioners authorized to initiate ADHD treatment. Other Australian states considering similar moves. These expand access while maintaining training, guidelines, and oversight.
- The Protocol: A Modest Proposal for Sanity — Two reforms: (1) Replace static APQ system with dynamic quotas responsive to actual prescription data, distinguishing medical use from trafficking. (2) Train primary care physicians to diagnose and manage ADHD with clinical guidelines and peer review.
Key Examples
- DEA Aggregate Production Quotas (APQs) — Federal Register 2024: annual limits on Schedule II stimulant manufacturing, not adjusted for rising legitimate demand.
- Patient experience — described as “living neck deep in cold molasses” (ADHD Advisor); calling dozens of pharmacies monthly, going weeks without medication.
- Telehealth expansion post-pandemic — connected more adults to proper ADHD care, driving demand increase that quotas did not accommodate.
- NSW reforms (The Guardian, May 2025) — GPs authorized to diagnose ADHD and prescribe stimulants, reducing specialist bottleneck and wait times.
- PHARMAC (New Zealand) announcement — GPs and nurse practitioners able to initiate ADHD treatment from the following year.
- DEA defense: quotas are “necessary for public safety” — piece treats this as self-defeating: untreated ADHD also creates safety risks.
Connections
- Drug Enforcement Administration — the agency controlling the quota system
- DEA Aggregate Production Quotas 2025 — Federal Register — the specific policy mechanism at issue
- ADHD — the condition and its treatment landscape
- NSW Health Reforms — the international comparator model
- Federal Trade Commission — mentioned by analogy in the broader newsletter context around regulatory capture
- Telehealth — the access expansion that drove demand increase quotas did not match
What It Leaves Open
- Whether removing specialist-only gatekeeping would actually lead to over-prescription, and what evidence exists from countries that have already expanded access.
- The piece proposes “dynamic quotas responsive to actual prescription data” but does not specify who sets the targets, what the lag is, or how the DEA would be reformed structurally to enable this.
- The connection between the DEA’s quota system and the broader opioid crisis response — the piece implies drug-war logic carried over, but the political economy of why reform is blocked is not examined.
- Whether telemedicine ADHD prescribing companies (which drove much of the post-pandemic demand increase) face a separate legitimacy problem the piece does not address.
Newsletter Context
Personal-stakes policy piece published the same day as the rebrand announcement. Uses sarcasm as primary rhetorical mode (unusual for the newsletter’s more analytical voice in later pieces). The DEA APQ system is a case study in regulatory capture by drug-war ideology: an enforcement agency setting medical supply limits based on abuse-prevention logic rather than patient-need data. Connects to the newsletter’s power beat: who controls access to medicine, and on what grounds. The international comparison (Australia, New Zealand successfully expanding access) frames U.S. policy as a choice, not a constraint. The author’s own neurodivergent identity (ADHD-autism) gives this piece implicit personal stakes, though it is less explicitly autobiographical than the AI rights series.